Medicare has proposed limiting coverage of Aduhelm, a costly new drug to treat Alzheimer’s disease, and prominent groups are pressing to make it more available. But among those facing the disease, the outlook is nuanced.
Join The Ecosystem
Medicare has proposed limiting coverage of Aduhelm, a costly new drug to treat Alzheimer’s disease, and prominent groups are pressing to make it more available. But among those facing the disease, the outlook is nuanced.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.